Scholarlink

<p>The rapid spread of respiratory viruses and their similar symptomatology pose significant challenges for early diagnosis, transmission control, and effective clinical management. We introduce a multianalyte diagnostic platform based on plasmonics for the rapid identification, discrimination, and quantification of viral antigens for the most common respiratory viruses (SARS-CoV-2, Influenza A/B, and RSV) in nasopharyngeal swabs. The biosensor chips are functionalized with four specific antibodies targeting viral nucleoproteins and are integrated into a single-use microfluidic cartridge, reaching low detection limits (ng/mL level). A clinical validation with positive and negative samples (<i>n</i> = 46) demonstrates an excellent correlation with PCR-based molecular tests. Furthermore, the novel diagnostic platform exhibits high sensitivity (97.22%) and specificity (100%), overcoming limitations associated with rapid antigen tests. Together with its accuracy and user-friendly design, our multibiosensor is positioned as a disruptive diagnostic tool for rapid and multiplexed diagnosis of viral infections at the point-of-care.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Disposable Point of Care multiplexed plasmonic biosensor for rapid and specific identification of respiratory viruses

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月13日

查看全文
  • Patricia Ramirez-Priego,
  • Juliana F. Giarola,
  • Cristina Andrés,
  • Andrés Antón,
  • M.-Carmen Estévez,
  • Laura M. Lechuga

摘要

The rapid spread of respiratory viruses and their similar symptomatology pose significant challenges for early diagnosis, transmission control, and effective clinical management. We introduce a multianalyte diagnostic platform based on plasmonics for the rapid identification, discrimination, and quantification of viral antigens for the most common respiratory viruses (SARS-CoV-2, Influenza A/B, and RSV) in nasopharyngeal swabs. The biosensor chips are functionalized with four specific antibodies targeting viral nucleoproteins and are integrated into a single-use microfluidic cartridge, reaching low detection limits (ng/mL level). A clinical validation with positive and negative samples (n = 46) demonstrates an excellent correlation with PCR-based molecular tests. Furthermore, the novel diagnostic platform exhibits high sensitivity (97.22%) and specificity (100%), overcoming limitations associated with rapid antigen tests. Together with its accuracy and user-friendly design, our multibiosensor is positioned as a disruptive diagnostic tool for rapid and multiplexed diagnosis of viral infections at the point-of-care.